论文部分内容阅读
抗CD2 0抗体治疗非霍奇金淋巴瘤 (NHL)已成为研究热点 ,因其与传统治疗相比 ,具有低毒高效的优点 ,从而为众多患者带来福音。现综述抗CD2 0抗体治疗惰性或侵袭性NHL方面的研究进展
Anti-CD20 antibody treatment of non-Hodgkin’s lymphoma (NHL) has become a research hotspot, because it has the advantage of low toxicity and high efficiency compared with traditional treatment, so as to bring good news to many patients. The progress of anti-CD20 antibodies in the treatment of inert or aggressive NHL is reviewed